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Three infants with ambiguous genitalia and suspected ovotestes were given recombinant FSH to induce ovarian follicular
development. The development of follicles in the gonadal tissue suggested the presence of ovarian tissue in two of the three
infants. This method may provide a means to better characterize gonadal anatomy in patients aﬀected by disorders of sex
development (DSD). Sonographic information poststimulation provided parents with earlier and more speciﬁc education and
support concerning the possible need for conﬁrmative gonadal biopsy treatment options.
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1.Introduction
Ovotesticular disorder of sex development (DSD) [1], for-
merlyknownastruehermaphroditism,ischaracterizedbythe
presence of both ovarian and testicular tissue in the gonads
of an individual. The traditional approach to establishing a
diagnosis of ovotesticular DSD has included history, physical
examination, evaluation of chromosomes, sex steroid secre-
tion, imaging of internal anatomy and laparoscopy as the
gold standard of establishing the diagnosis. Diﬀerentiating
the neonatal gonads (testess and ovaries) by sonographic
appearance alone is diﬃcult. In the setting of ambiguous
genitalia when no clear diagnosis has been established,
even with elevated testosterone, ovotestis must be suspected.
Performinglaparoscopyandbiopsy toestablishadiagnosis is
important for management decisions.
Exogenous FSH has been used for some time in fertility
treatments to induce multifollicular development [2]. Phar-
macological doses of FSH stimulate the growth of ovarian
follicles of various sizes. We report the use of FSH injections
in three infants with suspected ovotestes to induce ovarian
follicular development, both to determine if the patients
would have a responsive ovarian component to their gonads
and to enhance the use of sonography in assessing the
presence and location of gonads.
2. Patients andMethods
2.1. Patients. Three infants (ages 3 and 1/2 weeks, 6 weeks,
and 4 months) with ambiguous genitalia, 46XX karyotype,
and SRY negative were treated. Descriptions of their external
and internal genital structures are shown in Table 1.2 International Journal of Pediatric Endocrinology
Table 1: Description of external and internal genital structures.
Case External genitalia Internal genitalia assessed by US
1
1cm phallic structure, tip of urethra identiﬁed proximal to
apparent vaginal opening, nonfused labioscrotal structures,
hyperpigmented, nonrugated, no palpable gonads
No uterus: 0.8 × 0.5cm gonad visualized in inferior aspect of
the inguinal canal
2
1cm phallic structure, introitus opening with urethra, labio-
scrotal structures partially fused, non-hyperpigmented, right
gonad palpable in inguinal canal
Hypoplastic uterus: 2.5cm in length with a 0.2cm fundus,
0.2cm cervix; right inguinal gonad 0.9 × 0.6 × 0.8cm, left
inguinal gonad 0.6 × 0.6cm
3
1.8cm phallic structure with ventral urethra, fused labioscro-
tal structure, hyperpigmented with ruggae. No introitus or
vaginal opening. No palpable gonads
No uterus: right pelvic gonad 0.65 × 0. 68 × 0.7cm; left
inguinal gonad 0.9 × 0.12 × 0.6cm
Left
gonad
(a) (b)
1 1
2
2 Right
gonad
Pre-FSH
(c)
Post-FSH
(d)
Figure 1: Case1: pelvic ultrasound pre- and post-FSH; left gonad pre-FSH: 0.6cm × 0.4cm × 0.4cm = 0.05cc; left gonad post-FSH: 0.8cm
× 0.5cm × 0.6cm = 0.1cc; right gonad pre-FSH: 2.4cm × 1.3cm × 1.6cm = 2.61cc; right gonad post-FSH: 1.9cm × 0.9cm × 1.2cm ×
1.07cc (normal ovarian volume for age [3]: 1.05cc, SD 0.67, normal testicular volume [4] ≤1c c ) .
2.2. Methods. Each infant was given subcutaneous recombi-
nant human FSH (rhFSH-alpha, Gonal-f RFF manufactured
by Merck Serono SA) at 25 units per day for 3 days. The dose
was extrapolated from adult literature as per the treatment
guidelines for in vitro fertilization. The adult dose of rhFSH
is 150IU subcutaneous daily. When this dose is adjusted
using body surface area (150IU/1.73m2), the equivalent
dose for a newborn approximates 25IU. Ultrasound evalu-
ation was performed after FSH was administered (day 4) and
compared to ultrasounds obtained previously (range: 4 days
to 3 months prior). HCG stimulation tests were performed
by administering Pregnyl 500units/1.73m2 intramuscularly
once, with testosterone concentration drawn 72 hours later.
Testosterone and estradiol were measured by HPLC with a
detection limit of 3ng/dl and 0.1ng/dl, respectively (Eso-
terix).
Case 1. Pelvic ultrasound performed when the infant was 2
months old demonstrated a right inguinal gonad, considered
to be consistent with testicular tissue. The left inguinal canal
had minimal gonadal tissue with surrounding ﬂuid. No
uterus was identiﬁed, and no evidence of a tumor was found.
Serumtestosteroneat3daysoflifewas0.5nmol/L(15ng/dl).
Two months later, it had increased to 3.4nmol/L (97ng/dl)
and prior to 4 months was 7.6nmol/L (220ng/dl).
A recombinant FSH stimulation test was performed
when the infant was 4 months old. The post-FSH ultrasound
revealed numerous gonadal cystic structures, with more on
the left gonad than on the right, suggesting these gonads
represented ovotestes (Figure 1). Once again, no uterus was
seen. Post-FSH estradiol was 0.2nmol/L (5.6ng/dl). Serum
testosterone at that time was 12.5nmol/L (360ng/dl). The
elevated testosterone concentration likely was not a result ofInternational Journal of Pediatric Endocrinology 3
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Figure 2: Histopathologic features from the bilateral gonadal excisions (representative images from Case3) demonstrated features of
ovotestes (a)–(c) with ovarian stroma and primary and primordial follicles (b) in close proximity to seminiferous tubules with testicular
stroma (c). Cases1 and 2 demonstrated similar histopathologic ﬁndings, with the gonadal biopsies submitted for microscopic examination.
(hematoxylin and eosin staining, original magniﬁcation: (a) 200x, (b) and (c) 400x).
FSH stimulation but represented physiologic mini-puberty
of infancy [5]; however, we have no control data for conﬁr-
mation.
On laparoscopy, Mullerian remnants were noticed con-
sisting of a gonad and fallopian tube adjacent to the
gonad with a ﬁmbriated end noted bilaterally. On the
right, mullerian structures were observed consistent with
a fallopian tube. The infant underwent bilateral oophorec-
tomy, right orchidopexy, and bilateral inguinal hernia repair.
Histopathologic examination of the right and left gonadal
biopsies revealed features of an ovotestis with both ovarian
and testicular tissue present (Figures 2(a)–2(c)). The ovarian
tissue was comprised of ovarian stroma and primordial and
primary follicles (Figures 2(a) and 2(b)) . The testicular
tissue demonstrated seminiferous tubules with occasional
spermatogonia and testicular stroma (Figures 2(a) and
2(c)). The histopatho logic features of the ovotestis tissue
from all three cases were similar, as illustrated in Figure 2
(representative images from Case 3). Case 3 is representative
of histopathology of the ovotestes seen in all 3 cases. There
is no diﬀerence in the ovotestes histopathology among the 3
cases).
Microscopic examination of the entirely submitted um-
bilicalandrightinguinalherniasactissuesdemonstratedfea-
tures associated only with typical hernia sacs. Chromosome
studies from gonadal biopsy tissues revealed 46, XX and were
negative for SRY.
Case 2. Pelvic ultrasound performed when the infant was 2
weeks old demonstrated a small uterus with an endometrial
stripe and absent ovaries. Bilateral inguinal hernias with
apparent gonads in the hernia sacs also were seen (Figure 3).
No cysts were detected within the gonads. Associated
epididymal tissue appeared to be present, suggesting that
the gonads likely represented testicles. Serum testosterone
concentrationwas6.9nmol/L(198ng/dl)whenthechildwas
16 days old.
An HCG stimulation test was administered when the
child was 6 weeks old. Post-HCG testosterone concentration
was 4.5nmol/L (131ng/dl). A recombinant FSH stimulation
test was performed. The post-FSH ultrasound demonstrated
a new single cyst in the left gonad (Figure 3). The cyst
had the appearance of a follicle, suggesting that this
gonad likely represented an ovary. Post-FSH serum testos-
terone was 6.6nmol/L (190ng/dl), and estradiol 0.02nmol/L
(0.5ng/dl). The estradiol was this low possibly because the
ovarian tissue may have been dysfunctional and resistant but
not anatomically dysgenetic.
On laparoscopy, a right intraabdominal gonad was
observed with mullerian remnant and no vas deferens and
on the left an inguinal gonad was observed with a mulle-
rian remnant.The infant underwent bilateral oophorectomy,
orchidopexy, and inguinal hernia repair. Upon histopatho-
logic examination, the bilateral gonadal biopsies revealed
both ovarian and testicular tissue similar to that illustrated
in Figure 2 (representative images from Case 3), conﬁrming
the presence of an ovotestis. In addition, a fallopian tube
with epididymal tissue in close proximity was identiﬁed. The
completely submitted left hernia sac showed only features
of a typical hernia sac. Chromosome studies from gonadal
biopsy tissues revealed 46, XX.
Case 3. Pelvic ultrasound performed when the infant was 2
weeks old demonstrated a rounded, relatively homogeneous
structure in the right hemipelvis consistent with a gonad.
Because no follicles were seen, it was diﬃcult to determine
if this structure represented an ovary or a testicle. A
second gonadal structure with a central echogenic stripe
(typical of the mediastinum of a testicle) was seen in
the left hemipelvis. The apparent mediastinum suggested
this gonad represented a testicle. Surrounding soft tissue
material suggested an epididymis, further suggesting the
gonad was a testicle. An HCG stimulation test performed
when the infant was 2 weeks old resulted in a serum testos-
terone increase from 0.9nmol/L (27ng/dl) to 9.5nmol/L
(273ng/dl).
A recombinant FSH stimulation test was performed
when the child was 3 weeks old. The post-FSH ultrasound
was unchanged (Figure 4). Post-FSH, serum testosterone
was 7.3nmol/L (210ng/dl), and estradiol <0.02nmol/L
(<0.5ng/dl), see Table 2.4 International Journal of Pediatric Endocrinology
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Figure 3: Case2: Pelvic ultrasound pre- and post-FSH. Left gonad pre-FSH: 1.0cm × 0.6cm × 0.6cm = 0.19cc. Left gonad post-FSH:
1.8cm × 1.1 (3rd dimension not measured). Right gonad pre-FSH: 0.9cm × 0.6cm × 0.8cm = 0.23cc. Right gonad post-FSH: 0.9cm ×
1.3cm × 0.9cm = 0.55cc (normal ovarian volume for age = 1.06cc, SD 0.96, normal testicular volume ≤1c c ) .
Table 2: Steroids pre- and post-FSH including normative data.
Case Estradiol pre FSH Estradiol post-FSH Testosterone pre-FSH Testosterone post-FSH
(nmol/L) (nmol/L) (nmol/L) (nmol/L)
1 Not tested 0.2 Nl: 2–4 7.6 Nl: 2–4 12.5 Nl: 2–4
2 Not tested 0.02 Nl: 6–9 4.5 Nl: 6–9 6.6 Nl: 6–9
3N o t t e s t e d <0.02 NL: 3–6 6 NL: 3–6 7.3 NL: 3–6
Laparoscopy revealed Mullerian remnants bilaterally.
The infant underwent bilateral oophorectomy, orchidopexy,
and inguinal hernia repair. Histopathologic examination of
the bilateral gonadal biopsies and excisions demonstrated
features of ovotestes, as illustrated in Figure 2 (represen-
tative images from Case 3). The ovarian tissue contained
typical stroma with relatively frequent primary and pri-
mordial follicles (Figure 2(b)). Microscopic examination of
the entirely submitted bilateral inguinal hernia sac tissues
failed to reveal fallopian, epididymal, uterine, or Mullerian
structures. Chromosome studies with FISH analysis from
the biopsy samples revealed low level mosaicism for XXY
in 1 percent of cultured cells analyzed; the rest were
46XX.
3. Discussion
In North America, ovotesticular DSD is a rare occurrence.
The highest incidence is found in Africa [6].
Human menopausal gonadotropins (hMG) or ultra-
sonography has been used in the past to diagnose ovotes-
ticular DSD, but both tests have limitations. Mendez et al.
[7] demonstrated that an hMG challenge was able to
identify ovarian tissue based on a speciﬁed rise in estradiol;
however, the hMG challenge required waiting 6 to 8 weeks
after a 4-day hCG stimulation test was performed and
monitoring estradiol concentrations for up to 14 days.
Sonographic evaluation of ovotestes also has been reported,
but not all cases of ovotestes are detected with ultrasoundl
[8].
Because of the duration of time needed with the hMG
challenge and the inadequate sensitivity of ultrasonography,
our Gender Medicine Team used an innovative approach,
FSH stimulation testing, in three cases (two Hispanic infants
and one African American/Hispanic infant) in an attempt to
overcome these limitations. Using adult studies, a safe dose
was extrapolated, adjusting for body surface area.
The FSH method was applied as an innovative tool
to increase the sensitivity of ultrasound in the evaluation
of ovotestes and to determine the presence of ovarian
tissue. The use of rhFSH in these cases was intended as
a diagnostic tool and was considered a nonexperimental
innovation, in which the outcome of an innovation can
be reliably predicted [9, 10]. Non-experimental innovation
is a common practice in pediatrics, and consent to use it
shouldbeobtainedfromthepatientorthepatient’ssurrogate
[10, 11].International Journal of Pediatric Endocrinology 5
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Figure 4: Case3: Pelvic ultrasound pre- and post-FSH. Left gonad pre-FSH: 1.2cm × 0.6cm × 0.8cm = 0.3cc. Left gonad post-FSH: 1.3cm
× 0.5 (third dimension not measured). Right gonad pre-FSH: 0.7cm × 0.7cm × 0.5cm = 0.13cc. Right gonad post-FSH: 0.8cm × 0.5cm
× 0.8cm = 0.17cc (normal ovarian volume for age = 1.06cc, SD 0.96, normal testicular volume ≤1c c )
The presence of follicles in portions of the gonadal
tissue after FSH stimulation suggested the diagnosis of
ovotestis by ultrasound in two of the three infants. All
three cases later were conﬁrmed by gonadal biopsy. In
one case, follicles in the gonads developed only after FSH
stimulation. In a second case, follicles increased in size and
number after FSH stimulation, providing a more conclusive
sonographic diagnosis of ovotestes. In the third case, no
follicles were seen before or after FSH stimulation. No
abdominal ﬁndings were manifested, and there was no
pathologic evidence of the ovaries when biopsy results were
available. In retrospect, it may have been helpful to have
pre-FSH estradiol concentrations. It appears that a longer
duration of FSH therapy, or delayed estradiol follow-up, is
requiredtoappreciateanincreaseinestradiol. Nosideeﬀects
were reported or observed, including breast development,
clitoromegaly, vaginal bleeding, vomiting, diarrhea or ﬂuid
retention.
The FSH stimulation test, when compared with the
previously reported hMG challenge, was of shorter duration
and utilized imaging of stimulated gonadal tissue in place
of estradiol concentrations. In each of our cases, the FSH
stimulation testing provided for earlier diagnosis and earlier
visualization of the gonads, thereby allowing the parents
to consider the therapeutic options at an earlier date than
otherwise was possible [12]. Identifying ovotestes facilitates
the discussion of sex assignment at an earlier date than
otherwise possible. When these cases demonstrated that FSH
stimulation could be a useful diagnostic tool, we submitted
a proposal to our IRB to test the sensitivity and speciﬁcity
of this hypothesis, which was recently approved. There are
no previous reports of FSH being used for this speciﬁc
indication.
A recent report from Steinmetz et al. examined the use
of combined LH and FSH injections to evaluate testosterone,
estrogen, and inhibin A response in a cohort of patients with
DSD [13]. The study cohort included patients with DSD
(mean age: 8.4 years) and females with congenital adrenal
hyperplasia (CAH) as the positive-ovarian tissue controls
[13]. The subjects received the adult recommended dose of
LH/FSH, 150IU, subcutaneously daily for a total of 3 days
[13]. No imaging studies were obtained after the stimulation
was performed. A robust estradiol and inhibin A response
occurredintheDSDgroup,similartotheoneobservedinthe
CAH females, demonstrating the eﬀectiveness of combined
LH/FSH injections to identify functional ovarian tissue by
measuring in blood samples speciﬁc secretory products of
ovarian tissue [13].
In contrast to that study, our approach aimed to increase
theyieldofultrasonographybystimulatingfollicleformation
from ovarian tissue in infants with DSD. Hence, we opted to
use FSH, the gonadotropin with a predominant stimulatory
role in follicle formation. The approach of measuring pre-
and poststimulation concentrations of estradiol and inhibin
A has the advantage of providing biochemical identiﬁcation
of ovarian tissue, and, in combination with the ultrasanog-
raphy, should provide an ideal substitute for laparoscopy,
which is considered the gold standard. Our approach with
FSH stimulation relies on the principle of inducing follicle
formation to enhance the yield of ultrasonography and,
therefore, does not require a signiﬁcant amount of blood
to be drawn. As a safety precaution, we adjusted the FSH6 International Journal of Pediatric Endocrinology
dose for body surface area, which signiﬁcantly decreased the
concentration of the FSH delivered to our infant subjects
and may have limited the formation of follicles in our third
case. This infant was the youngest patient, and the FSH
stimulation test was performed when the infant was 2 weeks
old. We speculate that a higher dose of FSH may be necessary
in neonates as they undergo a physiological “mini puberty”
period in which LH and FSH are known to be the highest in
the life cycle [5].
4. Conclusion
Using recombinant FSH to stimulate the development of
sonographically identiﬁable follicles in ovotestes allowed us
to establish the diagnosis of ovotesticular DSD earlier in two
of our three cases. In conclusion, the use of FSH stimulation
followed by ultrasonography and the measurements of
estradiol and inhibin A may help preclude the need for
laparoscopy and biopsy in this population and thereby con-
tributetotheattempttoprovidelessinvasiveinterventionsin
the treatment of ambiguous genitalia. Nonetheless, as more
studies are needed in this area, laparoscopy remains the gold
standard. The conﬁrmation of our hypothesis of the advan-
tageofcombiningFSHstimulationandultrasonographywill
require further studies to establish sensitivity and speciﬁcity.
Furthermore, additional research is required to address the
optimal recombinant FSH dosing, the timing of followup
evaluation, and the addition of hormonal assays to conﬁrm
the early diagnosis of ovotesticular DSD. We, therefore, are
continuing our studies under the recently approved IRB, and
our study is open for recruitment.
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